Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868803 · ClinicalTrials.gov registry record
Aberrant Gene Expression Prostate Carcinoma
A clinical trial of Prostate Cancer, sponsored by Lahey Clinic.
- Active
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT00868803: Active study of Prostate Cancer, sponsored by Lahey Clinic.
NCT00868803 is a study of Prostate Cancer that is active but no longer recruiting, run by Lahey Clinic. The registered enrollment target is 5,000 participants, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868803, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Lahey Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
Conditions Studied
Study Locations (1)
Massachusetts
- Lahey Clinic - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 1995-04 |
| Est. Completion | 2030-04 |
What the registry record for NCT00868803 still lists
NCT00868803 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00868803 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00868803 about?
NCT00868803 is a clinical study titled "Aberrant Gene Expression Prostate Carcinoma". The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
What is the current status of trial NCT00868803?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 1995-04. Estimated completion is 2030-04.
What conditions does trial NCT00868803 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT00868803?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00868803 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00868803's enrollment target sits among peer trials
5,000 12th of 735 higher than 722 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia